Progression of sarcopenia among patients with pancreatic ductal adenocarcinoma receiving neoadjuvant therapy and the impact of pancreatic enzyme replacement therapy
{{output}}
Background: Neoadjuvant therapy (NAT) is increasingly used among patients with pancreatic ductal adenocarcinoma (PDAC). Patients with PDAC commonly present with sarcopenia, which may progress during the period of NAT and subseque... ...
